CCIA
AMLX icon

Campbell & Co Investment Adviser’s Amylyx Pharmaceuticals AMLX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$756K Sell
54,422
-24,341
-31% -$342K 0.04% 602
2025
Q4 		$951K Buy
78,763
+54,281
+222% +$737K 0.05% 584
2025
Q3 		$333K Buy
+24,482
New +$230K 0.03% 878

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Campbell & Co Investment Adviser's AMLX Position: Q1 2026 in Review

Campbell & Co Investment Adviser reduced its Amylyx Pharmaceuticals (AMLX) stake by 31% in Q1 2026, selling an estimated $342K and leaving 54,422 shares worth $756K. The position accounts for 0.04% of the portfolio, ranked #602.

Campbell & Co Investment Adviser first reported a position in AMLX in Q3 2025 and has held it in 3 quarters since. The position peaked at $951K in Q4 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Campbell & Co Investment Adviser held 54,422 shares of Amylyx Pharmaceuticals worth $756K as of Q1 2026.
  • Campbell & Co Investment Adviser sold 24,341 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $342K.
  • Amylyx Pharmaceuticals made up 0.04% of Campbell & Co Investment Adviser's portfolio in Q1 2026, its #602 holding.
  • Campbell & Co Investment Adviser first reported a position in Amylyx Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Campbell & Co Investment Adviser's Amylyx Pharmaceuticals position peaked at $951K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.